Search
Pemigatinib
go.drugbank.com/drugs/DB15102ApprovedInvestigationalThis malignancy accounts for 15% to 20% of primary hepatobiliary malignancies, which account for 13% of overall cancer-related global mortality. … growth factor receptor 2 (FGFR2) gene fusion or other rearrangements as detected by an FDA-approved test.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesEtrasimod
go.drugbank.com/drugs/DB14766ApprovedInvestigational2-mg daily dose regimen of etrasimod, with a 32% and 26% remission rate observed in UC 52 and UC 12 trials respectively. … Etrasimod is a synthetic next-generation selective Sphingosine 1-phosphate (S1P) receptor modulator that targets the S1P<sub>1,4,5</sub> with no detectable activity on S1P<sub>2</sub> and S1P<sub>3</sub
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C19 SubstratesMolindone
go.drugbank.com/drugs/DB01618ApprovedMolindone has much lower affinity for D2 receptors than most antipsychotic agents and has a relatively low affinity for D1 receptors. … An indole derivative effective in schizophrenia and other psychoses and possibly useful in the treatment of the aggressive type of undersocialized conduct disorder.
Categories: Dopamine D2 Receptor AntagonistsMinaprine
go.drugbank.com/drugs/DB00805ApprovedMinaprine is an amino-phenylpyridazine antidepressant reported to be relatively free of cardiotoxicity, drowsiness, and weight gain. … Minaprine is a psychotropic drug which has proved to be effective in the treatment of various depressive states. Like most antidepressants minaprine antagonizes behavioral despair.
Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates, Cytochrome P-450 SubstratesIloperidone
go.drugbank.com/drugs/DB04946ApprovedInvestigational[A3024] It is considered to be a second-generation antipsychotic drug [A263552] with multiple receptor binding profile, although it shows high affinity towards 5-HT<sub>2A</sub> and dopamine D2 receptors … Iloperidone is a benzisoxazole [A263557] and an atypical antipsychotic agent that was first approved by the FDA on May 6, 2009.
Categories: Dopamine D2 Receptor Antagonists, Cytochrome P-450 SubstratesAI-850
go.drugbank.com/drugs/DB05842ExperimentalAI-850 is a Cremophor(R)-free formulation of paclitaxel, the active ingredient in Taxol(R), a product used to treat a variety of solid tumors.
Palovarotene
go.drugbank.com/drugs/DB05467ApprovedIt first garnered interest as a potential treatment for emphysema but was eventually recognized as a potential novel therapy for patients with FOP. … ], which are derivatives of [vitamin A].
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 InducersDoxecitine
go.drugbank.com/drugs/DB02594ApprovedInvestigationalDoxecitine is currently approved and marketed as a fixed-dose combination therapy with [thymidine] (KYGEVVI). … Doxecitine is a synthetic form of the naturally occurring pyrimidine deoxyribonucleoside deoxycytidine.
Synonyms: MT-1621 COMPONENT 2'-DEOXYCYTIDINE, dCDinutuximab
go.drugbank.com/drugs/DB09077ApprovedInvestigationalneuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy. … It is indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk
Genistein
go.drugbank.com/drugs/DB01645InvestigationalAn isoflavonoid derived from soy products. It inhibits protein-tyrosine kinase and topoisomerase-II (DNA topoisomerases, type II) activity and is used as an antineoplastic and antitumor agent. … It has been investigated in clinical trials as an alternative to classical hormone therapy to help prevent cardiovascular disease in postmenopausal women [A14417].
Mixtures: CALCIDAY G 1200 MG/800 IU/50 MG EFERVESAN TABLET, 45 ADET, CALCİDAY G 1000 MG/880 IU/50 MG EFERVESAN TABLET, 40 ADETCategories: Compounds used in a research, industrial, or household setting, Cytochrome P-450 Substrates